Sweden · Delayed Price · Currency is SEK Carasent AB Earnings Call Transcripts
Fiscal Year 2026
-
ARR grew 16% year-over-year with strong profitability and 19% growth in the Nordics, while German revenues declined due to legacy churn. AI-driven product enhancements and Medsum adoption are key growth drivers, with share buybacks and targeted acquisitions planned.
Fiscal Year 2025
-
Q4 saw 15% organic ARR growth, a 16% EBITDA margin, and strong profitability, driven by major client migrations and high consulting revenues. AI investments continue, with Medsom now using OpenAI, and the sales pipeline remains robust, especially in the Nordics.
-
Q3 saw 16% organic ARR growth, 29% EBITDA margin, and strong cost control, with major product rollouts in Germany and Scandinavia. Revenue timing in Q4 depends on key project implementations, while SEK 70 million was spent on share buybacks, leaving a SEK 170 million cash balance.
-
Revised targets reflect project delays, restructuring, and increased AI investment, but ARR and recurring revenue continue to grow. Key wins in Västra Götaland and strong AI product development support a positive outlook, though execution risks remain.
-
EBITDA margin turned positive to 6% and revenue grew 29% year-over-year, driven by strong organic and acquired growth. AI investments and receivable write-downs slightly increased costs, but cash flow and ARR remain robust. Focus continues on growth, efficiency, and targeted M&A.
Fiscal Year 2024
-
Q4 saw strong ARR and margin growth, driven by the Data-Al acquisition and cost efficiencies. One-off costs impacted EBITDA, but underlying profitability and cash flow remain robust. Outlook is positive, with key projects and market changes expected to fuel growth in 2024-2025.
-
The acquisition of Data-AL enables immediate entry into Germany's large, fragmented EHR market, leveraging local expertise and a stable customer base. The deal is expected to drive revenue growth through cloud migration, with integration and commercial rollout of Webdoc X planned over the next few years.
-
Q3 saw strong organic growth, improved EBITDA, and higher gross margins, with robust contract wins and a positive outlook for continued expansion. One-time costs from relisting and acquisitions impacted results, but cost control and efficiency measures are driving profitability.
-
Delivered 15% recurring revenue growth and improved margins, with major new contracts signed and strong cost control. Relisting to Nasdaq Stockholm and product launches position the company for accelerated growth and profitability in the coming year.